Nacuity Pharmaceuticals develops targeted therapies to address oxidative tissue damage, which is associated with eye diseases and serious chronic conditions. The company has clinical programs for conditions such as retinitis pigmentosa, cataract, and cystinosis.

Nacuity Pharmaceuticals

Nacuity Pharmaceuticals, Inc. | 459 followers on LinkedIn. Leader in innovative treatments for oxidative stress | Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company’s powerful, targeted therapies aim to stop oxidative tissue damage, a driver of many blinding eye diseases and a broad spectrum of serious chronic conditions. Powered by key backing and technical support from the world’s leading private funders of retinal disease research, Foundation Fighting Blindness and RD Fund, Nacuity is pursuing near-term proof-of-concept data in several of its highly differentiated clinical programs, including retinitis pigmentosa, cataract, and cystinosis, with the potential to be first-of-a-kind therapies and gateways to wider applications.

President at Opus Genetics

Ben Yerxa

Vice President Integrated Drug Development & Certara Global Health Lead

Kevin Hershberger

Managing Director, RD Fund

Rusty Kelley

Owner - Talisman Healthcare

Daniel Feller

Nacuity Pharmaceuticals, Inc.

Nacuity has become aware that purported “recruiters” are fraudulently posing as representatives of Nacuity. These “recruiters” are reaching out on social media with fake offers of employment and asking potential “recruits” for personal and banking information. These “recruiters” do not represent Nacuity. They are completely unaffiliated with Nacuity. It is a scam. Nacuity is not actively recruiting at this time. No representative of Nacuity is soliciting personal or banking information. Image Description: Nacuity logo on white background with the text: "Beware: Fraudulent Recruiter Contact"

Our SVP and CSO, G. Michael Wall, Ph.D. , attended the American Association of Pharmaceutical Scientists Annual Meeting ( #PharmSci360 ) this week in Salt Lake City, UT. Dr. Wall had the opportunity to learn about the latest updates during the scientific sessions and liaise with global contract research and manufacturing organizations necessary for our drug development programs. Image description for photo #1: Dr. Michael Wall at AAPS opening session Image description for photo #2: Dr. Michael Wall in front of windows overlooking AAPS exhibit floor

G. Michael Wall, Ph.D. , our SVP and CSO, attended CPHI Milan, October 8-10, 2024. Chemical and Pharmaceuticals Ingredients (CPhI) Worldwide is the world’s largest pharma event, a 3-day exhibition bringing together more than 47,000 professionals and 2,600 exhibitors from more than 150 countries. Dr. Wall successfully identified sources for materials and services necessary for Nacuity’s drug development programs. Image Description: Dr. Michael Wall in Fiera Milano exhibition center #CPHI2024 #CPHIMilan

We look forward to joining our peers in #ophthalmology to learn more about the latest innovations at #AAO2024 in Chicago this week! We’re also excited for our onsite board of directors and scientific advisory board meetings. Check out this year’s program: https://lnkd.in/dCK33m7

Today is #WorldSightDay and this year is focused on children’s eye health. Eye diseases, like RP associated with Usher syndrome, are often diagnosed during childhood. Vision is critical to a child’s development. Join the International Agency for the Prevention of Blindness (IAPB) to take the pledge to make children’s eye health and awareness a priority! https://brnw.ch/21wMEaU

For #BlindnessAwarenessMonth , the Foundation Fighting Blindness ’ #ShareYourVision campaign invites individuals experiencing #VisionLoss to share their stories and unique experiences of life after diagnosis. We’re proud to join FFB to share patient stories and help raise awareness of blinding #EyeDiseases . Follow the #ShareYourVision hashtag to learn more!

This Sunday is #WorldRetinaDay and World #RetinitisPigmentosa Day (RP). The retina makes vision possible and retinal diseases like #RP lead to #VisionLoss in millions of people worldwide. Our commitment to patients affected by blinding #EyeDiseases drives our work to develop our #OxidativeStress therapies for the treatment of RP and more. Image Description: Photo of eye and Nacuity Pharmaceuticals logo on green and blue background with the text "September 29 World Retina Day & World Retinitis Pigmentosa Day"

Finding treatments and cures for rare diseases like Usher syndrome is often limited by insufficient research and funding, making spreading awareness for #UshDay a critical part of our mission to improve the lives of people experiencing #visionloss . Join us and the #UsherSyndrome community to help shine a light on this inherited disease. Image Description: Photo of child putting glasses on doll and Nacuity Pharmaceuticals logo on green and blue background with the text "September 21 Usher Syndrome Awareness Day 400,000 people worldwide are affected by #USH ."

Although #UsherSyndrome (USH) is considered a #raredisease , it’s the leading cause of combined deafness and #blindness worldwide. We’re advancing our clinical trial evaluating of our NPI-001 tablets to treat #retinitispigmentosa associated with #USH to improve the lives of individuals with USH. Learn more and follow our progress: https://lnkd.in/etgtbbHV Image Description: Spotlight on Usher Syndrome logo at the top left with text below that says, "An estimated 25,000 people in the U.S. have Usher syndrome. Worldwide, it is the leading cause of combined deafness and blindness." To the right is a blue DNA double helix.

We’re a proud sponsor of the Usher Syndrome Coalition 's USH Connections Conference. #USH2024 is an important opportunity to connect #UsherSyndrome patients and families with researchers working to advance #USH treatments and professionals serving the #DeafBlind community. Learn more: https://lnkd.in/edWnwR8s

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

Google Maps

WordPress

CEO/President

Halden Conner

Sr. Vice President, Chief Clinical Officer

Jami Kern

Sanford Hillsberg

Benjamin Yerxa

David Wohlberg

Isaac Blech

CEO & President

Health Care Companies (Top 10K)

Dallas/Fort Worth Metroplex Early Stage Companies

Pharmaceutical Early Stage Companies With Fewer Than 1000 Employees

Southern US Early Stage Companies With Less Than $500M in Revenue

Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa (“RP”) and potentially other ophthalmological indications.

Nacuity has assembled an accomplished team and has received significant financial and technical support from the Foundation Fighting Blindness (FFB). FFB aims to drive research providing prevention, treatments and cures for people affected by blinding retinal diseases. 

FFB has invested nearly $700 million in this effort Over the last 46 years. FFB is a significant supporter of Dr. Campochiaro’s research and has committed to fund a substantial portion of Nacuity’s Phase 1 and Phase 2 trials through a milestone-based matching program grant to Nacuity in support of our NPI-001 development program.

Foundation Fighting Blindness

Series B - Nacuity Pharmaceuticals

Series A - Nacuity Pharmaceuticals

Venture Round - Nacuity Pharmaceuticals

Computer and Software Services and Scientific Services

Fort Worth

Texas

United States

North America

G. Michael Wall, Ph.D. on LinkedIn: G. Michael Wall, PhD, SVP & CSO for Nacuity, attended the…

Opthalmic Industry Veteran Joins Nacuity Pharmaceuticals' Board

Opthalmic Industry Veteran Joins Nacuity Pharmaceuticals’ Board

Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.

Arctic Therapeutics and Nacuity Pharmaceuticals Announce European Medicines Agency Approval to Initiate First ...

Nacuity Pharmaceuticals Expands Business Advisory Board

Nacuity Pharmaceuticals, Inc. on LinkedIn: Nacuity has become aware that purported “recruiters” are fraudulently…

Nacuity Pharmaceuticals Announces Expansion of its Business Advisory Board with Appointment of Rare Disease ...

Cystinosis Pipeline and Clinical Trials 2023: Latest FDA Approvals, Therapeutic Advancements, Treatment, and K

A small molecule treatment developed to slow or halt disease progression in retinitis pigmentosa patients with functioning cones, regardless of their disease-causing genetic mutation.

An intravitreal implant containing a small molecule antioxidant intended to slow cataract progression, delivered via a proprietary injector.

An oral dosage form containing a small molecule antioxidant for the treatment of nephropathic cystinosis.

A proprietary ophthalmic insert containing a small molecule antioxidant for the treatment of the ocular effects of cystinosis.

An oral dosage form containing a small molecule antioxidant for the treatment of a rare neurological disease.

news impact assignment basic	general
public peers	general	Nov 18, 2024 11:22 AM	cdf1aaf2
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 18, 2024 11:22 AM	556ae952
crunchbase trigger	general	Nov 18, 2024 11:22 AM	aa6442d9
crunchbase profile	general	Nov 18, 2024 11:25 AM	9576d2bd
li profile	general	Nov 18, 2024 11:22 AM	17059682
translate crunchbase fundingrounds	general	Nov 18, 2024 11:53 AM	fc7e6a8d
peers	general	Nov 18, 2024 11:22 AM	2ffd5c4d
news basic	general	Nov 18, 2024 11:22 AM	49d7128b
bundesanzeiger	filings
financials download nd	financials
private financials	financials

NACU

COM:NACUITY

Nacuity Pharmaceuticals